BioCatalystWatch
RFLWorkspace / RFL / OverviewCompany library

Rafael Holdings, Inc.

Rafael Holdings, Inc. (RFL)

Website

Price
Market cap
Next catalystFebruary 2027 — full Phase 3 results at a medical meetingRemibetadex (Trappsol® Cyclo™) — TransportNPC core study · Phase 3 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

Licensed products containing hydroxypropyl-beta-cyclodextrin

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Licensed products containing hydroxypropyl-beta-cyclodextrin

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Other pipelines

Devimistat (CPI-613)

PreINDP1P2P3FilingApproved
Devimistat (CPI-613)

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Partner / License out

Approved / commercial

Approved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

Approved

PreINDP1P2P3FilingApproved

History / paused

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

RFL SEC archive